Sareum Holdings PLC AGM NOTICE (2487H)
November 14 2018 - 2:01AM
UK Regulatory
TIDMSAR
RNS Number : 2487H
Sareum Holdings PLC
14 November 2018
(AIM: SAR) 14 November 2018
Sareum Holdings plc
("Sareum" or "the Company")
Notice of AGM and Annual Report & Accounts
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, has notified its shareholders that its
Annual General Meeting ("AGM") will take place at 10.00 a.m. on 18
December 2018 at the offices of Citigate Dewe Rogerson, 3 London
Wall Buildings, London Wall, London EC2M 5SY.
On 13 November 2018, the Company Annual Report and Accounts for
the year ended 30 June 2018 was posted to shareholders who
requested a hard copy and the notice convening the 2018 AGM was
posted to all shareholders. A copy of both documents has been
placed on the Company website www.sareum.co.uk.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory
responses in autoimmune diseases (e.g. psoriasis, rheumatoid
arthritis, inflammatory bowel diseases and lupus) and tumour cell
proliferation in certain cancers (e.g. T-cell acute lymphoblastic
leukaemia and some solid tumours). The Company is targeting first
human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAEAKFDFSKPFFF
(END) Dow Jones Newswires
November 14, 2018 02:01 ET (07:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024